Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;109(3):230-231.
doi: 10.1097/JS9.0000000000000018.

Therapeutic implication of chimeric antigen receptor T-cell therapy for head and neck squamous cell carcinoma

Jayanthi Pazhani  1 , Selvaraj Jayaraman, Vishnu Priya Veeraraghavan
Affiliations

Therapeutic implication of chimeric antigen receptor T-cell therapy for head and neck squamous cell carcinoma

Jayanthi Pazhani et al. Int J Surg. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial conflict of interest with regard to the content of this report.

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Figures

Figure 1
Figure 1
CAR T cells have an extracellular domain with scFv component that recognizes the target antigen independent of MHC. The transmembrane domain connects the extracellular component to an intracellular signaling domain composed of co-stimulatory molecules, which triggers the downstream T-cell activation. In contrast, TCRs are heterodimers consisting of α and β subunit that recognizes intracellular antigen presented by MHC. CAR, chimeric antigen receptor; MHC, major histocompatibility complex; scFv, single chain variable fragment, TCR, T-cell receptor.
See this image and copyright information in PMC

Comment in

References

    1. Leon X, Orus C, Casasayas M, et al. Trends in disease-specific survival of head and neck squamous cell carcinoma patients treated in a single institution over a 30-year period. Oral Oncol 2021;115:105184. - PubMed
    1. Kirtane K, Elmariah H, Chung CH, et al. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer 2021;9:e002723. - PMC - PubMed
    1. Jafferji MS, Yang JC. Adoptive T cell therapy for solid malignancies. Surg Oncol Clin N Am 2019;28:465–479. - PubMed
    1. Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol 2018;200:459–468. - PMC - PubMed
    1. Abate-Daga D, Davila ML. CAR models: next generation CAR-modifications for enhanced T cell function. Mol Ther Oncolytics 2016;18:16014. - PMC - PubMed

MeSH terms

Substances